ICML 2017 | Key therapeutic advances in follicular lymphoma

Andrew Davies

Andrew Davies, MD, BSc, MRCP, PhD, from the University of Southampton, Southampton, UK provides an overview of the key therapeutic advances in follicular lymphoma at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. He briefly touches on new therapies based on pathway inhibition, BCR signaling, PI3 kinase inhibition, BTK inhibition and the microenvironment. He has discussed in detail data from the GALLIUM study (NCT01332968) which compared the combinations of rituximab and chemotherapy against obinutuzimab and chemotherapy. There has been encouraging results regarding the main outcome studied – investigator assessed progression free survival. However Dr Davies mentions he has been particularly intrigued by the toxic effects that have occurred when combining the chemotherapeutic agent bendamustine with either obinutuzimab or rituximab. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

Share this video